Literature DB >> 10160489

French economic evaluations of influenza and influenza vaccination.

E Levy1.   

Abstract

The cost-of-illness studies of influenza performed in France or the years 1985 and 1989 have shown that the major economic consideration in the respective sizes of indirect and direct costs. Depending on the point of view (from the perspective of National Health Insurance or the societal perspective) and the method used for measuring indirect costs, it was estimated that they could be between 1.5 and 9 times higher than direct costs. A cost-benefit study of influenza vaccination for the employed adult population showed that vaccination is a cost-saving strategy, although this was also contingent upon the problems associated with measuring indirect benefits as well as the effectiveness rate of vaccination in real conditions.

Mesh:

Substances:

Year:  1996        PMID: 10160489     DOI: 10.2165/00019053-199600093-00014

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  3 in total

1.  Cost-of-illness studies: a major headache?

Authors:  M Drummond
Journal:  Pharmacoeconomics       Date:  1992-07       Impact factor: 4.981

Review 2.  Costs of illness in cost-effectiveness analysis. A review of the methodology.

Authors:  T A Hodgson
Journal:  Pharmacoeconomics       Date:  1994-12       Impact factor: 4.981

3.  [Anti-influenza vaccination for active persons (25-64 years): a cost-benefit study].

Authors:  E Levy; P Levy
Journal:  Rev Epidemiol Sante Publique       Date:  1992       Impact factor: 1.019

  3 in total
  18 in total

1.  Economic evaluations of influenza vaccination in healthy working-age adults. Employer and society perspective.

Authors:  S C Wood; V H Nguyen; C Schmidt
Journal:  Pharmacoeconomics       Date:  2000-08       Impact factor: 4.981

Review 2.  Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidence.

Authors:  M J Postma; R M Baltussen; M L Heijnen; L T de Berg; J C Jager
Journal:  Drugs Aging       Date:  2000-09       Impact factor: 3.923

Review 3.  Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence.

Authors:  Maarten J Postma; Paul Jansema; Marianne L L van Genugten; Marie-Louise A Heijnen; Johannes C Jager; Lolkje T W de Jong-van den Berg
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  A model to estimate the cost benefit of an occupational vaccination programme for influenza with Influvac in the UK.

Authors:  Roben Das Gupta; Julian F Guest
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 5.  Antiviral agents for influenza: a comparison of cost-effectiveness data.

Authors:  Larry D Lynd; Ron Goeree; Bernie J O'Brien
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 6.  Influenza vaccines. A reappraisal of their use.

Authors:  A M Palache
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

Review 7.  Influenza. The role of burden-of-illness research.

Authors:  T D Szucs
Journal:  Pharmacoeconomics       Date:  1999       Impact factor: 4.981

Review 8.  Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.

Authors:  G He; J Massarella; P Ward
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

Review 9.  Interventions to increase influenza vaccination rates of those 60 years and older in the community.

Authors:  Roger E Thomas; Diane L Lorenzetti
Journal:  Cochrane Database Syst Rev       Date:  2014-07-07

Review 10.  Reducing the burden of influenza-associated complications with antiviral therapy.

Authors:  B R Ruf; T Szucs
Journal:  Infection       Date:  2009-05-26       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.